Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charles River Acquires KWS BioTest | Contract Pharma

What are you searching for?

Sign in
Breaking News

Charles River Acquires KWS BioTest

Expands discovery services for immuno-oncology, inflammatory, and infectious diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories has acquired KWS BioTest, a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory, and infectious diseases, for approximately $20 million. 
 
The acquisition expands Charles River’s discovery services with additional tools in the growing therapeutic research areas of oncology and immunology. The transaction also includes a potential additional payment of as much as $4 million based on future performance.
 
James C. Foster, chairman, president and chief executive officer of Charles River, said, “The addition of KWS strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system.  In addition to enhancing our position as the premier single-source provider for a broad portfolio of discovery services, KWS increases our ability to support clients’ early-stage drug research in critical therapeutic areas, and expands our geographic footprint in the UK.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics